Ascendiant Capital Markets Cuts AIM ImmunoTech (NYSE:AIM) Price Target to $4.50

AIM ImmunoTech (NYSE:AIM) had its price target decreased by Ascendiant Capital Markets from $5.00 to $4.50 in a research note published on Tuesday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Separately, Maxim Group cut their price objective on shares of AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday, October 22nd.

AIM ImmunoTech Price Performance

Shares of NYSE AIM opened at $0.21 on Tuesday. The firm has a 50-day simple moving average of $0.24 and a 200-day simple moving average of $0.31. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $13.58 million, a price-to-earnings ratio of -0.45 and a beta of -0.36. AIM ImmunoTech has a 52 week low of $0.16 and a 52 week high of $0.62.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC bought a new position in shares of AIM ImmunoTech Inc. (NYSE:AIM) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned 7.92% of AIM ImmunoTech at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.02% of the company’s stock.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).